What is the 13F Pro Quality Score for CDNA?

13F Pro ranks CareDx, Inc. (CDNA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CDNA's current score at https://13fpro.ai/research/CDNA (free sign-up required for the full ranking).

Which hedge funds own the most CDNA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CDNA include BlackRock,, BAMCO /NY/, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/CDNA as soon as new 13F filings post.

Where does 13F Pro source CDNA data?

All CareDx, Inc. fundamentals and ownership data come directly from SEC EDGAR. CareDx, Inc. files with the SEC under CIK 1217234. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CDNA in?

CareDx, Inc. (CDNA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CDNA research updated on 13F Pro?

CDNA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

CareDx, Inc.(CDNA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1217234 CDNA stock profile & AI dashboard →

13F Pro Quality Score

44.8/100

Rank #1,750 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

77.2/100

Profitability

41.9/100

Balance Sheet

26.6/100

Earnings Quality

30.0/100

Free Cash Flow

50.7/100

Institutional Flow

41.3/100

Revenue Scale

33.1/100

Dilution Risk

17.8/100

CDNA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for CareDx, Inc. (CDNA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CDNA at 44.8/100 on a 32-signal composite quality model, placing it at rank #1,750 of 2,879 stocks — the bottom half of the AI-ranked universe. CDNA scores in the top quartile across revenue growth (77.2). Areas of concern include balance sheet strength (26.6) and earnings quality (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 17.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), CareDx, Inc. reports quarterly revenue of $117.7M, net income of $2.8M, free cash flow of $514.0K. Top institutional holders of CDNA by reported 13-F value include BlackRock,, BAMCO /NY/, STATE STREET, based on the most recent SEC filings. CDNA trades on the Nasdaq exchange and files with the SEC under CIK 1217234. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CDNA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CareDx, Inc. directly from SEC EDGAR. CareDx, Inc.'s 13F Pro composite quality score has ranged between 8 and 70 since 2021, currently 44.8 — a stable long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about CareDx, Inc.

Quirks, history, and lore behind CDNA — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare technology company · small-cap · listed on Nasdaq · headquartered in California.
2
The Numbers
Annual revenue in the low hundreds of millions of dollars, built almost entirely on testing and surveillance services for a very specific patient population.
3
The History
Founded in the late 1990s, the company spent years quietly cornering a niche before going public on Nasdaq under a ticker that hints at DNA.
4
The Secret
Its core business is monitoring whether a patient's body is rejecting a transplanted organ — using cell-free DNA tests to catch rejection before symptoms even appear.
5
The Lore
Its flagship test, AlloSure, analyzes donor DNA circulating in a recipient's bloodstream — essentially letting a transplanted heart or kidney send an SOS signal through a blood draw.
6
The Giveaway
If you've ever had a transplant and your doctor ordered a liquid biopsy to check for rejection, there's a good chance this company — whose ticker literally spells CDNA — ran that test.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$117.7M

Net Income

Q1 2026

$2.8M

Free Cash Flow

Q1 2026

$514.0K

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+13.8% YoY

$379.8MFY 2025

FY22 $321.8MFY23 $280.3MFY24 $333.8MFY25 $379.8M

Net Income

-140.6% YoY

$-21.4MFY 2025

FY22 $-76.6MFY23 $-190.3MFY24 $52.5MFY25 $-21.4M

Operating Income

-175.5% YoY

$-30.8MFY 2025

FY22 $-77.2MFY23 $-203.4MFY24 $40.8MFY25 $-30.8M

EPS (Diluted)

-143.0% YoY

$-0.40FY 2025

FY22 $-1.44FY23 $-3.54FY24 $0.93FY25 $-0.40

Total Assets

-15.8% YoY

$413.2MFY 2025

FY22 $543.0MFY23 $466.8MFY24 $491.1MFY25 $413.2M

Total Debt

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Op. Cash Flow

+10.5% YoY

$42.0MFY 2025

FY22 $-25.2MFY23 $-18.4MFY24 $38.0MFY25 $42.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$379.8M +13.8%	$333.8M +19.1%	$280.3M -12.9%	$321.8M +8.6%	$296.4M +54.2%	$192.2M
Net Income	$-21.4M -140.6%	$52.5M +127.6%	$-190.3M -148.4%	$-76.6M -149.9%	$-30.7M -63.8%	$-18.7M
Operating Income	$-30.8M -175.5%	$40.8M +120.0%	$-203.4M -163.3%	$-77.2M -159.8%	$-29.7M -32.0%	$-22.5M
EPS (Diluted)	$-0.40 -143.0%	$0.93 +126.3%	$-3.54 -145.8%	$-1.44 -144.1%	$-0.59 -47.5%	$-0.40
Total Assets	$413.2M -15.8%	$491.1M +5.2%	$466.8M -14.0%	$543.0M -4.2%	$566.6M +53.8%	$368.5M
Total Debt	—	—	—	—	—	$0.00
Operating Cash Flow	$42.0M +10.5%	$38.0M +306.9%	$-18.4M +27.1%	$-25.2M -30.8%	$-19.3M -157.7%	$33.4M

Get alerted when CDNA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CareDx, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CDNA

BlackRock, Inc.
$78.5M4,522,096 sh
BAMCO INC /NY/
$57.9M3,336,409 sh
STATE STREET CORP
$47.9M2,760,385 sh
ARK Investment Management LLC
$38.7M2,227,556 sh
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$38.0M2,191,000 sh
BRAIDWELL LP
$37.7M2,173,146 sh
VANGUARD CAPITAL MANAGEMENT LLC
$37.5M2,160,457 sh
Boston Partners
$32.7M1,883,534 sh
GAGNON SECURITIES LLC
$30.6M1,761,874 sh
Chevy Chase Trust Holdings, LLC
$26.1M1,504,075 sh

Fund	Value	Shares
BlackRock, Inc.	$78.5M	4,522,096
BAMCO INC /NY/	$57.9M	3,336,409
STATE STREET CORP	$47.9M	2,760,385
ARK Investment Management LLC	$38.7M	2,227,556
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	$38.0M	2,191,000
BRAIDWELL LP	$37.7M	2,173,146
VANGUARD CAPITAL MANAGEMENT LLC	$37.5M	2,160,457
Boston Partners	$32.7M	1,883,534
GAGNON SECURITIES LLC	$30.6M	1,761,874
Chevy Chase Trust Holdings, LLC	$26.1M	1,504,075

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CDNA on your watchlist

Track score changes the day CareDx, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CDNA a good stock to buy?

13F Pro's AI-powered analysis of CareDx, Inc. (CDNA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CDNA are available on the CDNA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CDNA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CDNA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CareDx, Inc.'s investment landscape.